PublisherThe University of Arizona.
RightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
AbstractDiabetic retinopathy is a leading cause of vision loss among working age adults. As of right now, the only treatment is for advanced stages, either through surgical intervention or intravitreal injections. These procedures are both invasive and expensive and only stabilize vision loss, not prevent it or restore what has been lost. The purpose of this research is to study early stage Type I diabetes in the retina in order to identify future targets for treatment or prevention. We use a mouse model and immunohistochemical labeling to view the GlyRα1 receptors in the retinas. The localization of GlyRα1 receptors are then compared to control injected mice to find changes caused by diabetes. We found there to be no difference in the localization of the GlyRα1 receptors in diabetic and non-diabetic mice. This suggests the GlyRα1 receptor is not affected by diabetes at the early stage of six-weeks. Future studies will focus on the GlyRα1 and GABAA-α1 receptors at 12 weeks of induced diabetes in mice.
Degree ProgramHonors College